You are here

Imatinib Mesylate Discontinuation in Patients With CML Treated with Front-Line IM Therapy and Achieved Complete Molecular Response

sandy craine's picture
Submitted by sandy craine on Mon, 25/06/2012 - 7:13pm
Ho-Young Yhim, Na-Ri Lee, Eun-Kee Song, Chang-Yeol Yim, So Yeon Jeon, Seunghwan Shin, Jeong-A Kim, Hee Sun Kim, Eun Hae Cho, Jae-Yong Kwak Division of Hematology/Oncology, Department of Internal Medicine, Republic of Korea.

Ho-Young Yhim, Na-Ri Lee, Eun-Kee Song, Chang-Yeol Yim, So Yeon Jeon, Seunghwan Shin, Jeong-A Kim, Hee Sun Kim, Eun Hae Cho, Jae-Yong Kwak
Division of Hematology/Oncology, Department of Internal Medicine, Republic of Korea.

ASCO 2012:

sandy craine's picture
Submitted by sandy craine on Mon, 11/06/2012 - 3:46pm
PACE: Robust and Durable Antileukemic Responses With Ponatinib in Patients With Heavily Pretreated, Refractory CML or Ph+ ALL Posting Date: June 06, 2012 Updated analysis of PACE: single-arm phase II trial[1] Summary of Key Conclusions: www.clinicaloptions.com/Oncology/Conference>

PACE: Robust and Durable Antileukemic Responses With Ponatinib in Patients With Heavily Pretreated, Refractory CML or Ph+ ALL
Posting Date: June 06, 2012

Updated analysis of PACE: single-arm phase II trial[1]
Summary of Key Conclusions:
www.clinicaloptions.com/Oncology/Conference>

Minimal Residual Disease

sandy craine's picture
Submitted by sandy craine on Thu, 10/05/2012 - 12:56pm
Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib E Weisberg1,5, A K Azab1,5, P W Manley2, A L Kung3, A L Christie3, R Bronson4, I M Ghobrial1 and J D Griffin1 Abstract: Drug resistance is a growing area of concern. It has been shown that a small, residual pool of leukemic CD34+ progenitor cells can survive in the marrow microenvironment of chronic myeloid leukemia (CML) patients after years of kinase inhibitor treatment.....read more

Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib
E Weisberg1,5, A K Azab1,5, P W Manley2, A L Kung3, A L Christie3, R Bronson4, I M Ghobrial1 and J D Griffin1

Abstract:
Drug resistance is a growing area of concern. It has been shown that a small, residual pool of leukemic CD34+ progenitor cells can survive in the marrow microenvironment of chronic myeloid leukemia (CML) patients after years of kinase inhibitor treatment.....read more

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.

sandy craine's picture
Submitted by sandy craine on Sat, 10/03/2012 - 11:51am

Blood. 2012 Feb 27. [Epub ahead of print] - Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.

Blood. 2012 Feb 27. [Epub ahead of print] - Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.

Pages